PD L1 News and Research

RSS

FDA grants accelerated approval to cancer treatment based on common biomarker

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).

23 May 2017

Study findings could lead to quick and new way for predicting efficacy of cancer treatments

Once hailed as a breakthrough in cancer treatment, immunotherapies are now raising concerns as doctors note new side effects like severe allergic reactions, acute-onset diabetes and heart damage.

23 May 2017

Researchers show how cancer therapy works in different way to destroy tumor cells

Antibodies to the proteins PD-1 and PD-L1 have been shown to fight cancer by unleashing the body's T cells, a type of immune cell.

18 May 2017

Recurrence of HPV-negative HNSCC after radiation therapy linked to high tumor levels of PD-L1 protein

Recurrence of head and neck squamous cell carcinoma (HNSCC) negative for human papillomavirus (HPV) following radiation therapy was associated with high tumor levels of the protein PD-L1.

5 May 2017

New research identifies immunotherapy targets to offer hope for early-stage lung cancer patients

Immunotherapy, which has achieved remarkable results in late-stage lung cancer patients, can also hold great hope for newly diagnosed patients, cutting the deadly disease off before it has the chance to take hold and offering a potential cure, according to a new Mount Sinai study published today in Cell.

4 May 2017

Study suggests how existing and emerging immunotherapy treatments could be successful for sarcomas

Sarcomas- cancers of the connective tissues like muscles, joints, fat and bone -; come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers.

3 May 2017

Researchers find new way to prevent graft-versus-host disease after stem cell transplants

Through experimental work, an international team of researchers led by City of Hope's Defu Zeng, professor of diabetes immunology and hematopoietic cell transplantation, believe they may have found a way to prevent graft-versus-host disease after stem cell transplants while retaining the transplants' positive effects on fighting leukemia and lymphoma.

18 Apr 2017

Combination of anti-angiogenic and immune-stimulating therapies can lead to effective cancer treatments

Scientists from VIB and KU Leuven, together with colleagues from the University of California and the Swiss Institute for Experimental Cancer Research have demonstrated that, anti-angiogenic therapy can improve immune boosting treatments.

13 Apr 2017

ANGLE's Parsortix system shows high sensitivity, purity in gene expression analysis of head and neck cancers

ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE’s Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.

4 Apr 2017

Patients' immune system profiles could be linked to effectiveness of cancer immunotherapy

Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute.

3 Apr 2017

Study explores new immunotherapy combinations to treat prostate cancer

Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.

29 Mar 2017

FDA grants accelerated approval to new drug for treatment of rare form of skin cancer

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.

23 Mar 2017

Combination approach holds potential for treating lung cancer patients

An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects.

17 Mar 2017

New biomarker 'Bim' could help predict optimal treatment for metastatic melanoma patients

Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who were previously considered untreatable.

8 Mar 2017

Combination of epigenetic and immune-based treatments could lead to better blood cancer therapies

Researchers at Monash University and Peter MacCallum Cancer Centre have identified for the first time how a new class of epigenetic drug engages with the immune system to kill off cancer cells, offering powerful new pathways for enhanced blood cancer therapies.

1 Mar 2017

Melanoma patients' immunotherapy response linked to diversity and makeup of gut bacteria

Melanoma patients' response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO-Society for Immunotherapy in Cancer meeting in Orlando.

22 Feb 2017

Study paves way for therapies against myeloid-derived suppressor cells that collude with cancer

Some cells excite the immune system. Others soothe it. Myeloid-derived suppressor cells (MDSCs) are one type of soothing cell, and previous work shows that cancer may specifically boost production of MDSCs as a way to tamp down immune response against tumors. At least that's how it works in mice.

3 Feb 2017

New immunotherapy active against mucosal melanoma and improves survival for bladder cancer patients

Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma.

30 Jan 2017

Inactive B2M genes can condition response of lung cancer patients to immunotherapy, study shows

Researchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute have identified inactivating mutations in a number of genes that code for HLA-I histocompatibility complex proteins, which are involved in the immune response and can condition the tesponse of lung cancer patients to immunotherapy.

18 Jan 2017

Dual treatment strategies lengthen lives of mice with skin cancer

By combining two treatment strategies, both aimed at boosting the immune system's killer T cells, Johns Hopkins researchers report they lengthened the lives of mice with skin cancer more than by using either strategy on its own.

21 Dec 2016